Physician profile
Katie Arno
NPI 1720616477
$1,731.48
in general payments reported to CMS, 2019-2025
30 companies · $16.74 in 2025
The $16.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $252 · 2024: $1,463 · 2025: $16.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $255.75 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $194.16 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.32 | 2023-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $115.93 | 2023-2024 | |
| Pfizer INC. | $106.18 | 2023-2024 | |
| Lilly USA, LLC | $98.54 | 2024 | Mounjaro, Zepbound |
| Amgen INC. | $70.42 | 2023-2024 | Repatha, Otezla, Prolia |
| Alkermes, INC. | $64.40 | 2023-2024 | Vivitrol, Vivitrol |
| Collegium Pharmaceutical, INC. | $54.74 | 2024 | Xtampza |
| Scpharmaceuticals INC. | $51.59 | 2024-2025 | |
| Ucb, INC. | $51.39 | 2024 | Nayzilam |
| Neurocrine Biosciences, INC. | $50.18 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $48.55 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $46.97 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Scilex Pharmaceuticals INC. | $35.36 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.06 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $32.26 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $29.09 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $27.62 | 2024 | |
| Mylan Specialty L.P. | $26.11 | 2024 | Yupelri |
| Dexcom, INC. | $24.84 | 2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $23.55 | 2024 | Fanapt |
| Abiomed | $17.65 | 2024 | Impella |
| Glaxosmithkline, LLC. | $16.63 | 2024 | Shingrix, Arexvy |
| Neurelis, INC. | $16.62 | 2023 | Valtoco |
| Janssen Pharmaceuticals, INC | $16.38 | 2024 | Xarelto |
| Ardelyx, INC. | $15.90 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.45 | 2024 | Caplyta |
| Abbott Laboratories | $14.28 | 2024 | Freestyle Libre 3 |
| Corium, LLC | $13.56 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Arno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.